Search Results for "Afrezza"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Afrezza. Results 1 to 3 of 3 total matches.
See also: insulin
In Brief: An Expanded Indication for Afrezza
The Medical Letter on Drugs and Therapeutics • Oct 26, 2026 (Issue 1766)
In Brief: An Expanded Indication for Afrezza ...
The rapid-acting inhaled human insulin Afrezza (MannKind),
which was approved in 2014 for treatment of type 1 or type
2 diabetes in adults, has now been approved by the FDA for
use in children ≥6 years old.
Med Lett Drugs Ther. 2026 Oct 26;68(1766):174-5 doi:10.58347/tml.2026.1766d | Show Introduction Hide Introduction
Insulins for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Dec 08, 2025 (Issue 1743)
~35-55 mins 1.5-3 hrs 473.5014
Afrezza (Mannkind)
Rapid-Acting Insulin Analogs
Insulin aspart ...
The goal of pharmacologic treatment for type 2
diabetes is to achieve and maintain a near-normal
glycated hemoglobin (A1C) concentration while
minimizing hypoglycemia; an A1C goal of <7%
is recommended for most patients to prevent or
reduce the microvascular complications of diabetes
(retinopathy, nephropathy, neuropathy). An A1C target
of <8% may be appropriate for patients who are older,
have comorbid conditions, or are at risk for serious
hypoglycemia-associated adverse events.
Med Lett Drugs Ther. 2025 Dec 8;67(1743):196-9 doi:10.58347/tml.2025.1743c | Show Introduction Hide Introduction
Comparison Chart: Some Available Insulins for Type 2 Diabetes (online only)
The Medical Letter on Drugs and Therapeutics • Dec 08, 2025 (Issue 1743)
–
Afrezza (Mannkind)
4, 8, 12 units/inh
4, 8, 12 unit cartridges
12 mins
~35-55 mins
1.5-3 hrs ...
View the Comparison Chart: Some Available Insulins for Type 2 Diabetes
Med Lett Drugs Ther. 2025 Dec 8;67(1743):e201-4 doi:10.58347/tml.2025.1743d | Show Introduction Hide Introduction